Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CBLB | Q13191 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18687183 | 0.80 | GRM4 (0.32) | GRM4CHRNA7 | |
| SCHEMBL6921897 | 0.75 | ALOX15 (0.39) | GRM4ALOX15CHRNA7ALDH1A1CBLB | |
| SCHEMBL23691864 | 0.74 | GRM4 (0.34) | GRM4ALOX15CHRNA7CBLB | |
| SCHEMBL20853026 | 0.72 | PRKCI (0.31) | — | |
| SCHEMBL23937809 | 0.71 | PLK4 (0.41) | GRM4ALOX15CHRNA7ALDH1A1SMN1; SMN2 | |
| SCHEMBL20852941 | 0.70 | SCN5A (0.36) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL24037317 | 0.70 | ALOX15 (0.35) | GRM4ALOX15ALDH1A1HSD17B10 | |
| SCHEMBL12248509 | 0.70 | GRM4 (0.36) | GRM4ALOX15CHRNA7ALDH1A1SMN1; SMN2 | |
| SCHEMBL14234175 | 0.70 | GRM4 (0.36) | GRM4ALOX15CHRNA7CBLB | |
| SCHEMBL20852791 | 0.68 | SSTR4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9771337-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771337-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9499487-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GRM4 3531/4885ALOX15 4236/4885CHRNA7 849/4885 |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | GRM4 3871/4885ALOX15 3393/4885CHRNA7 1058/4885 |
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, TRPV3 | GRM4 205/4885ALOX15 289/4885CHRNA7 263/4885 |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | GRM4 3295/4885ALOX15 2841/4885CHRNA7 2278/4885 |
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GRM4 3531/4885ALOX15 4236/4885CHRNA7 849/4885 |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GRM4 3531/4885ALOX15 4236/4885CHRNA7 849/4885 |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | ERBB2, EGFR, ERBB3 | GRM4 3942/4885ALOX15 3228/4885CHRNA7 1016/4885 |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | ERBB2, EGFR, ERBB4 | GRM4 3295/4885ALOX15 2841/4885CHRNA7 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.